Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07562087 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
A Phase 2 study, sponsored by Tarsus Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 722
- Enrollment target
NCT07562087: Active Phase 2 study, sponsored by Tarsus Pharmaceuticals.
NCT07562087 is a Phase 2 study that is active but no longer recruiting, run by Tarsus Pharmaceuticals. The registered enrollment target is 722 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (443% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07562087, a Phase 2 study, is active but no longer recruiting, sponsored by Tarsus Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 722 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
Primary Outcome
Safety and tolerability will be evaluated by incidence rate of treatment emergent adverse events from baseline.
Interventions
- DRUG Placebo
- DRUG TP-05 (lotilaner) Low Dose
- DRUG TP-05 (lotilaner) High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What the registry record for NCT07562087 still lists
NCT07562087 is an interventional study that assigns participants to a tested intervention. The registered 722 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (443% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07562087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07562087 about?
NCT07562087 is a clinical study titled "A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure". This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
What is the current status of trial NCT07562087?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 722 participants. The study started on 2026-03-09. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07562087?
The interventions under investigation include: Placebo (DRUG), TP-05 (lotilaner) Low Dose (DRUG), TP-05 (lotilaner) High Dose (DRUG).
Who is sponsoring clinical trial NCT07562087?
This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07562087's enrollment target sits among peer trials
722 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06116149 · 722 participants · NA
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI